EP Patent

EP4578865A3 — Lymph directing prodrugs

Assigned to Monash University · Expires 2025-07-30 · 1y expired

What this patent protects

The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

USPTO Abstract

The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Drugs covered by this patent

Patent Metadata

Patent number
EP4578865A3
Jurisdiction
EP
Classification
Expires
2025-07-30
Drug substance claim
No
Drug product claim
No
Assignee
Monash University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.